Caspofungin-Resistant Candida tropicalis Strains Causing Breakthrough Fungemia in Patients at High Risk for Hematologic Malignancies

Guillermo Garcia-Effron,1 Dimitrios P. Kontoyiannis,2* Russell E. Lewis,2 and David S. Perlin1*

Public Health Research Institute, New Jersey Medical School, University of Medicine and Dentistry of New Jersey, Newark, New Jersey,1 and The University of Texas M. D. Anderson Cancer Center, Houston, Texas2

Received 18 June 2008/Returned for modification 23 August 2008/Accepted 7 September 2008

We identified three cases of C. tropicalis strains causing breakthrough fungemia in allogeneic stem cell recipients receiving caspofungin prophylaxis and treatment. Three genetically unrelated isolates with high echinocandin MICs were identified. Each strain carried a characteristic mutation conferring an amino acid substitution within Fks1p hot spot 1.

Echinocandins inhibit fungal cell wall biosynthesis through noncompetitive inhibition of 1,3-β-glucan synthase (GS) (4). These agents are widely used for treatment and prophylaxis of candidiasis in selected high-risk patients (2, 15). Although resistance in Candida species is uncommon (13, 14), clinical isolates of Candida spp. having increased echinocandin MICs and amino acid substitutions in Fksp have been described to occur in candidemic patients for whom caspofungin-based therapy has failed (1, 3, 6, 8, 11, 13). Candida tropicalis is an important pathogen in patients with hematologic malignancies (9). Recently, it was reported that a patient with acute myelogenous leukemia developed caspofungin-resistant C. tropicalis fungemia (12). Herein, we describe three additional cases of caspofungin-resistant C. tropicalis candidemia in patients at high risk for hematologic malignancies and characterize the resistance mechanism.

From March 2001, when caspofungin was introduced, until February 2007, we identified 40 C. tropicalis bloodstream isolates in 37 patients at the M. D. Anderson Cancer Center (isolates T1 to T40). The isolates were characterized as C. tropicalis by conventional and molecular methods (16). Three patients at high risk for hematologic malignancies who developed C. tropicalis fungemia breakthrough during caspofungin treatment were identified during this period, representing 8% (3/37) of the cases. Breakthrough C. tropicalis fungemia was defined as C. tropicalis septicemia during caspofungin administration (empirical or prophylactic).

Patient 1 (isolate T19). An 84-year-old male with acute

---

**TABLE 1. In vitro susceptibility testing and GS inhibition profiles for echinocandin drugs**

<table>
<thead>
<tr>
<th>Strain</th>
<th>Organism</th>
<th>Fks1p hot spot 1</th>
<th>MIC (µg/ml) ANF</th>
<th>IC₅₀ (ng/ml) ANF</th>
<th>IC₅₀ (ng/ml) CSF</th>
<th>IC₅₀ (ng/ml) MCF</th>
</tr>
</thead>
<tbody>
<tr>
<td>ATCC 750</td>
<td>C. tropicalis</td>
<td>FLTLSLRDP</td>
<td>0.06</td>
<td>0.25</td>
<td>0.06</td>
<td>4.661</td>
</tr>
<tr>
<td>T7*</td>
<td>C. tropicalis</td>
<td>FLTLSLRDP</td>
<td>0.12</td>
<td>0.50</td>
<td>0.06</td>
<td>2.689</td>
</tr>
<tr>
<td>T3*</td>
<td>C. tropicalis</td>
<td>FLTLSLRDP</td>
<td>2.00</td>
<td>4.00</td>
<td>2.00</td>
<td>0.320</td>
</tr>
<tr>
<td>T19*</td>
<td>C. tropicalis</td>
<td>FLTLSLRDP</td>
<td>1.00</td>
<td>4.00</td>
<td>2.00</td>
<td>0.574</td>
</tr>
<tr>
<td>T26*</td>
<td>C. tropicalis</td>
<td>FLTLSLRDP</td>
<td>0.50</td>
<td>1.00</td>
<td>0.50</td>
<td>31.62</td>
</tr>
<tr>
<td>ATCC 90028</td>
<td>C. albicans</td>
<td>FLTLSLRDP</td>
<td>0.03</td>
<td>0.12</td>
<td>0.03</td>
<td>1.830</td>
</tr>
<tr>
<td>205</td>
<td>C. albicans</td>
<td>FLTLPLRD</td>
<td>2.00</td>
<td>8.00</td>
<td>4.00</td>
<td>989.0</td>
</tr>
</tbody>
</table>

a ANF, anidulafungin; CSF, caspofungin; MCF, micafungin. Bold letters represent amino acid changes.
b This was a clinical echinocandin-susceptible isolate from another patient in this study. Azole MICs: fluconazole, 0.25 µg/ml; itraconazole, 0.25 µg/ml; voriconazole, 0.06 µg/ml; and posaconazole 0.25 µg/ml.
c Azole MICs: fluconazole, 8 µg/ml; itraconazole, 0.5 µg/ml; voriconazole, 1 µg/ml; and posaconazole, 0.25 µg/ml.
d Azole MICs: fluconazole, 32 µg/ml; itraconazole, 1 µg/ml; voriconazole, 2 µg/ml; and posaconazole 1 µg/ml.
e Azole MICs: fluconazole, 0.5 µg/ml; itraconazole, 0.125 µg/ml; voriconazole, 0.03 µg/ml; and posaconazole, 0.06 µg/ml.

* Corresponding author. Mailing address for Dimitrios P. Kontoyiannis: Department of Infectious Diseases, Infection Control and Employee Health, Unit 402, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030. Phone (713) 792-6237. Fax (713) 745-0839. E-mail: dkkontoyi@mdanderson.org. Mailing address for David S. Perlin: Public Health Research Institute, 225 Warren Street, Newark, NJ 07103. Phone: (973) 854-3200. Fax: (973) 854-3101. E-mail: perlinds@umdnj.edu.

f Published ahead of print on 15 September 2008.
lymphocytic leukemia started on intravenous caspofungin (50 mg/day) for persistent (despite broad-spectrum antibacterials) febrile neutropenia. Three sets of blood cultures obtained on days 15 and 16 of caspofungin treatment revealed low-grade (6 CFU) fungemia caused by \textit{C. tropicalis}. During the course of fungemia, the patient remained clinically stable, afebrile, and normotensive. The patient cleared his cultures 1 day after removal of his central venous catheter and initiation of intravenous voriconazole treatment (caspofungin was discontinued). He did well clinically after completing 2 weeks of voriconazole treatment and showed no evidence of recurrence until his death 8 months later from leukemia.

**Patient 2 (isolate T3).** A 59-year-old male with large-cell lymphoma who received a matched allogeneic hematopoietic stem cell transplant had a complicated course with renal failure and persistent \textit{Acinetobacter} bacteremia. The patient was on intravenous caspofungin at 50 mg/day as a posttransplant prophylaxis. Because of a persistent fever, all catheters were removed. However, on day 44 of caspofungin treatment, a peripheral blood culture was positive for both \textit{Pseudomonas aeruginosa} and \textit{C. tropicalis}. Antifungal treatment was changed to liposomal amphotericin B treatment (5 mg/kg of body weight/day). He cleared his blood cultures and showed no evidence of recurrent candidemia until his death 3 months later from lymphoma.

**Patient 3 (isolate T26).** A 45-year-old nonneutropenic male with a prior history of Hodgkin’s lymphoma, renal cell carcinoma, and esophageal cancer had multiple courses of bacterial pneumonia. In addition, the patient developed catheter-related \textit{Candida parapsilosis} fungemia and was treated with caspofungin at 50 mg/day, with clinical and mycologic responses. However, the patient developed recurrent fevers on day 21 of caspofungin. The catheter tip cultures grew 50 CFU/ml of \textit{C. tropicalis} and 30 CFU/ml of \textit{Staphylococcus epidermidis}. His antibiotics were adjusted, and caspofungin was switched to fluconazole (6 mg/kg/day). Although follow-up

![FIG. 1. Echinocandin inhibition profiles for product-entrapped GCs.](image)

![FIG. 2. DNA sequencing chromatograms and amino acid sequence alignment for \textit{C. tropicalis} strains.](image)
blood cultures became negative, he eventually succumbed to respiratory failure secondary to ventilator-associated pneumonia.

Echinocandin susceptibility testing of the 40 C. tropicalis strains was performed following CLSI (formerly NCCLS) document M27-A2 (10), with modifications (14). Echinocandin drugs exhibited potent in vitro activities against 92% (37/40) of the C. tropicalis strains tested, with MIC geometric means of 0.47 μg/ml (MIC₉₀ 0.5; range, 0.02 to 4.0), 0.13 μg/ml (MIC₉₀ 0.12; range, 0.06 to 2.0), and 0.23 μg/ml (MIC₉₀ 0.12; range, 0.06 to 2.0) for caspofungin, anidulafungin, and micafungin, respectively. However, the strains isolated from the patients described above showed 4- to 33-fold-higher MICs than a reference strain and exceeded or were at the maximum range reported for large collections of clinical isolates (14) (Table 1). The reduced in vitro susceptibilities to echinocandin drugs were confirmed in GS enzyme assays. Following GS isolation, echinocandin inhibition kinetics yielding 50% inhibitory concentrations (IC₅₀) were obtained (6, 11). The product of the reaction mixture was characterized as 1,3-β-glucan (5).

Table 1). In contrast, biphasic inhibition kinetics (with two IC₅₀) was obtained for the reference strain (ATCC 750), three clinical susceptible strains, and the T26 strain. However, T26 GS yielded higher IC₅₀ for all echinocandin drugs (Fig. 1 and Table 1). In contrast, biphasic inhibition kinetics (with two IC₅₀) was obtained for T3 and T19 GS enzymes (Fig. 1 and Table 1) (T3 data not shown). The highest IC₅₀ was at least 50-fold higher than the IC₅₀ obtained from susceptible GS enzymes. The presence of two inflection points in kinetic curves suggests mixed populations of wild-type and mutant GS enzymes (6, 11). Consistent with this notion, DNA sequence analysis of C. tropicalis FKS1 (GenBank accession no. EU676168) revealed a homozygous T-to-C mutation (in strain T26) and heterozygous T-to-C mutations (in strains T3 and T19) (equivalent to nucleotides T1923 and T1935 in Candida albicans FKS1 [GenBank accession no. XM 716336], respectively) (Fig. 2). These nucleotide changes resulted in deduced Phe-to-Leu (in the T26 strain) and Ser-to-Pro (in the T3 and T19 strains) amino acid changes. These amino acid substitutions are located in the highly conserved hot spot 1 region of Fks1p (Fig. 2), associated with echinocandin resistance in Candida spp. (3, 6, 11). These results provide additional support for Fks1p modification as a common mechanism for echinocandin resistance in Candida spp. (1, 3, 5, 6, 11, 13).

Echinocandin resistance is uncommon (13), creating skepticism regarding the value of routine MIC determination for the management of candidemic patients with these agents. Moreover, there is no compelling evidence that the rates of response to echinocandins for Candida isolates having elevated echinocandin MICs are inferior to the rates for isolates having low echinocandin MICs (7). Our report contributes to such knowledge, as it links FKS1 mutation, high echinocandin MICs, and clinical failures of echinocandin-based therapy. Moreover, in our cases of caspofungin-resistant C. tropicalis, the clinical courses were rather benign, in contrast to what has been published before with respect to C. tropicalis fungemia in patients at high risk for hematologic malignancies (9).

We thank Jeffrey Tarrand and Nick Sipsas for useful information and N. A. Albert for technical assistance.

D.P.K. has received research support and honoraria from Schering-Plough, Pfizer, Astellas Pharma, Inc., Enzon Pharmaceuticals, and Merck & Co., Inc. R.E.L. has received research support and honoraria from Schering-Plough, Astellas Pharma, Inc., Enzon Pharmaceuticals, and Merck & Co., Inc. This work was supported in part by NIH grant AI069397 to D.S.P.

REFERENCES


